Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis

作者全名："Li, Xuanmei; Huang, Xue; Lei, Lifu; Tong, Shiwen"

作者地址："[Li, Xuanmei] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Inst Viral Hepatitis, Dept Infect Dis,Minist Educ,Affiliated Hosp 2,Dept, Chongqing, Peoples R China; [Huang, Xue] Chongqing Med Univ, Affiliated Hosp 2, Dept Ultrasound, Chongqing, Peoples R China; [Lei, Lifu; Tong, Shiwen] Chongqing Med Univ, Affiliated Hosp 2, Dept Clin Nutr, Chongqing, Peoples R China"

通信作者："Tong, SW (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Clin Nutr, Chongqing, Peoples R China."

来源：FRONTIERS IN NUTRITION

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001097187400001

JCR分区：Q2

影响因子：4

年份：2023

卷号：10

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：primary liver cancer; sarcopenia; sarcopenic obesity; muscle depletion; survival

摘要："Background: Sarcopenia and sarcopenic obesity are associated with an increased possibility of adverse clinical outcomes; however, the effects of sarcopenia and sarcopenic obesity on patients with primary liver cancer remain controversial. Therefore, the present study aimed to determine the impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer.Methods: We searched studies published in English in PubMed, Embase, Web of Science, and Cochrane Library databases up to 13 November 2022. Cohort studies that reported the association among sarcopenia, sarcopenic obesity, and patient survival were included.Results: A total of 64 cohort studies with data on 11,970 patients with primary liver cancer were included in the meta-analysis. Sarcopenia was associated with poor overall survival in patients with primary liver cancer [adjusted hazard ratio (HR) 2.11, 95% confidence interval (CI): 1.89-2.36, P < 0.0001], with similar findings for sarcopenic obesity (adjusted HR: 2.87, 95% CI: 2.23-3.70, P < 0.0001). Sarcopenia was also associated with poor overall survival across the subgroups analyzed by ethnicity, type of liver cancer, treatment modalities, method used to define sarcopenia, and etiology of liver cancer. We also found a negative correlation among sarcopenia, sarcopenic obesity, and recurrence-free/disease-free survival (adjusted HR: 1.73, 95% CI: 1.50-1.99, P < 0.001; adjusted HR: 2.28, 95% CI: 1.54-3.35, P < 0.001, respectively).Conclusion: Sarcopenia and sarcopenic obesity were significantly associated with poor overall survival and recurrence-free/disease-free survival in patients with primary liver cancer.Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=378433, PROSPERO [42022378433]."

基金机构：　

基金资助正文：